IMPLICATIONS FOR PATIENT CARE: HER2- and CD24-targeted immuno-PET could prove valuable in the clinic as a theranostic tool to identify patients with endometrial cancer who are likely to respond to HER2- and CD24-targeted therapeutics. The gene discussed is CD24; the disease is endometrial cancer.